Art. -Nr.: HY-N3001

Isolinderalactone

1 Cited Publications

Kundenbewertung

Based on 1 publication(s) in Google Scholar

Isolinderalactone is a sesquiterpene that exhibits anti-cancer, anti-inflammatory, and neuroprotective effects. Isolinderalactone inhibits VEGF expression and tyrosine phosphorylation of VEGFR2. Isolinderalactone decreases viability and induces apoptosis in U-87 glioblastoma (GBM) cells and colorectal cancer (CRC) cells. Isolinderalactone induces G2/M phase cell cycle arrest, ROS generation, pJNK/p38 MAPK activation, in colorectal cancer (CRC) cells. Isolinderalactone blocks LPS (HY-D1056)-induced NF-κB activation while activating Nrf2-HMOX1 signaling in RAW264.7 macrophages. Isolinderalactone improves cognitive dysfunction in APP/PS1 mice. Isolinderalactone can be used for the study of Glioblastoma multiforme (GBM), colorectal cancer, Alzheimer’s disease and acute lung injury.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 98.79%
CAS. Nr.: 957-66-4
Formel: C₁₅H₁₆O₃
Molecular Weight:244.29

Speicherung:

4°C, sealed storage, away from moisture and light

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)

Isolinderalactone Chemical Structure

CAS. Nr.: 957-66-4

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Publications (1)
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

IC₅₀ & Target^[1]

VEGFR2

Bcl-2

Alle STAT Isoform-spezifische Produkte anzeigen :

Alle VEGFR Isoform-spezifische Produkte anzeigen :

Alle Bcl-2 Family Isoform-spezifische Produkte anzeigen :

Alle IAP Isoform-spezifische Produkte anzeigen :

Alle NF-κB Isoform-spezifische Produkte anzeigen :

Alle Caspase Isoform-spezifische Produkte anzeigen :

Cellular Effect

Cell Line	Type	Value	Description	References
RAW264.7	CC₅₀	66.41 μM Compound: 7	Cytotoxicity against mouse RAW264.7 cells assessed as reduction in cell viability after 3 hrs by alamar blue assay Cytotoxicity against mouse RAW264.7 cells assessed as reduction in cell viability after 3 hrs by alamar blue assay	[PMID: 22148193]
RAW264.7	IC₅₀	0.3 μM Compound: 7	Inhibition of iNOS-mediated NO production in LPS-stimulated mouse RAW264.7 cells after 24 hrs by Griess reagent method Inhibition of iNOS-mediated NO production in LPS-stimulated mouse RAW264.7 cells after 24 hrs by Griess reagent method	[PMID: 22148193]

In Vitro

Isolinderalactone (0.5-2.5 μg/mL, 24-72 h) inhibits U-87 glioblastoma cell growth^[1].
Isolinderalactone (0.5-2.5 μg/mL, 48 h) activates the apoptotic pathway in U-87 GBM cells by decreasing BCL-2, survivin, and XIAP expression, increasing cleaved caspase-3, and inducing DNA breakage, thereby promoting cell apoptosis^[1].
Isolinderalactone (0.5-2 μg/mL, 48 h) suppresses VEGF expression in U-87 GBM cells and inhibits VEGF-induced angiogenesis of human brain microvascular endothelial cells (HBMECs)^[2].
Isolinderalactone (2 μg/mL, 8 days) inhibits angiogenic sprouting in a 3D microfluidic chip^[2].
Isolinderalactone (2.5-5 μg/mL, 48 h) decreases HIF expression and activity in U-87 cells and VEGFR2 activation in HBMECs^[2].
Isolinderalactone (0-9 μM, 24-48 h) suppresses proliferation and colony formation of colorectal cancer cells (HCT116, HCT116-OxR, HT29, and HT29-OxR cells)^[3].
Isolinderalactone (0-9 μM, 48 h) induces apoptosis, G2/M cell cycle arrest, ROS generation, and ER stress in colorectal cancer cells^[3].
Isolinderalactone (0-9 μM, 48 h) induces apoptosis in CRC cells via mitochondrial and caspase-dependent pathways, potentially by modulating JNK/p38 MAPK activation, with ROS playing a critical role in this process^[3].
Isolinderalactone (10 μM, 2-27 h) attenuates Aβ_1-42-induced cell damage and reduces neurotoxicity in PC12 cells^[4].
Isolinderalactone (10 μM, 27 h) reduces neuronal cell damage by inhibiting JNK in PC12 cells^[4].
Isolinderalactone (0.5-10 μM, 19 h) inhibits LPS or TNF-α-induced inflammatory response in RAW264.7 cells, MH-S cells and BMDMs^[5].
Isolinderalactone (1-10 μM, 13 h) suppresses the mRNA expression of proinflammatory enzymes and cytokines in LPS-exposed RAW264.7 macrophages^[5].
Isolinderalactone (1-10 μM, 2-9 h) blocks LPS-induced NF-κB activation while activating Nrf2-HMOX1 signaling in RAW264.7 macrophages^[5].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[1][2]

Cell Line:

U-87 GBM cells and HBMECs
Concentration:

0.5, 1, 2, 2.5 μg/mL
Incubation Time:

24, 48, 72 h
Result:

Inhibited cell viability in a dose-dependent manner.
Decreased VEGF-induced HBMEC proliferation in a dose-dependent manner.

Western Blot Analysis^[1][2]

Cell Line:

U-87 GBM cells and HBMECs
Concentration:

0.5, 1, 2.5,5 μg/mL
Incubation Time:

48 h
Result:

Decreased BCL-2, survivin, and XIAP expression.
Increased the level of cleaved caspase-3 and cleaved PARP.
Decreased the expression of the potent angiogenic factor, VEGF.
Decreased HIF expression and activity in U-87 cells.
Reduced phosphorylation of VEGFR2 in HBMECs.

Immunofluorescence^[1]

Cell Line:

U-87 GBM cells
Concentration:

2.5 μg/mL
Incubation Time:

48 h
Result:

Showed predominantly bright γ-H2AX nuclear staining.

Cell Viability Assay^[3]

Cell Line:

HCT116, HCT116-OxR, HT29, and HT29-OxR cells
Concentration:

3, 6, 9 μM
Incubation Time:

24, 48 h
Result:

Suppressed colorectal cancer cells proliferation with IC₅₀ values of 8.05 μM (HCT116), 5.13 μM (HCT116-OxR), 10.38 μM (HT29) and 9.46 μM (HT29-OxR).

Cell Cycle Analysis^[3]

Cell Line:

HCT116, HCT116-OxR, HT29, and HT29-OxR cells
Concentration:

3, 6, 9 μM
Incubation Time:

48 h
Result:

Contributed to G2/M phase cell cycle arrest.

Western Blot Analysis^[3]

Cell Line:

HCT116, HCT116-OxR, HT29, and HT29-OxR cells
Concentration:

3, 6, 9 μM
Incubation Time:

48 h
Result:

Increased the expression levels of ER stress related proteins (GRP78, CHOP, DR4, and DR5).
Activated JNK/p38 MAPK.
Increased the levels of pro-apoptotic proteins (Bim and Bax), apaf-1, and cleaved (c)-PARP.
Decreased expression levels of anti-apoptotic proteins (Mcl-1, Bid, Bcl-xL and Bcl-2), mitochondrial cyto c and caspase 3 in a dose-dependent manner.

Western Blot Analysis^[4]

Cell Line:

Aβ_1-42-induced PC12 cells
Concentration:

10 μM
Incubation Time:

27 h
Result:

Decreased Bax expression and intracellular levels of caspase-3 activation and increased Bcl2 levels.
Decreased the level of p-JNK, but had no significant effect on ERK and P38MAPK.

Real Time qPCR^[5]

Cell Line:

LPS-exposed RAW264.7 macrophages
Concentration:

1, 10 μM
Incubation Time:

13 h
Result:

Decreased the mRNA levels of iNOS, COX2, IL-1β, IL-6, and TNF-α.

Western Blot Analysis^[5]

Cell Line:

LPS-exposed RAW264.7 macrophages
Concentration:

1, 5, 10 μM
Incubation Time:

2, 9 h
Result:

Down-regulated LPS-induced phosphorylation of IKKα/β and the level of NF-κB p65.
Increased the protein level of Nrf2 protein in the cytoplasmic fraction and nuclear fraction.

In Vivo

Isolinderalactone (1-5 mg/kg, i.p., every other day, 12 days) inhibits tumor growth in a human GBM xenograft mouse model^[1].
Isolinderalactone (2.5-5 mg/kg, i.p., every other day, 16 days) reduces tumor growth and vasculature in a human GBM xenograft model ^[2].
Isolinderalactone (5 mg/kg, i.p., daily, 6 days) inhibits VEGF-mediated angiogenesis in an in vivo Matrigel plug assay in mice^[2].
Isolinderalactone (1-10 mg/kg, i.p., daily, 30 days) ameliorates learning and memory deficits in APP/PS1 mice^[4].
Isolinderalactone (2.5-10 mg/kg, i.p., daily, 5 days) alleviates LPS-induced lung inflammatory injury in mice^[5].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

U-87 GBM cells (3 × 10⁶ cells/100 μL of serum-free DMEM) were subcutaneously implanted into the right flank of the BALB/C nude mice^[1]
Dosage:

1, 2.5, 5 mg/kg
Administration:

i.p., every other day for 12 days
Result:

Reduced tumor volume and weight Showed no differences on body weight.
Increased cleaved caspase-3 fluorescence.
Showed a significantly higher number of TUNEL-positive cells.

Animal Model:

U-87 GBM cells (3 × 10⁶ cells/100 μL of serum-free DMEM) were subcutaneously implanted into the right flank of the BALB/C nude mice^[2]
Dosage:

2.5, 5 mg/kg
Administration:

i.p., every other day for 16 days
Result:

Decreased tumor volume and suppressed tumor progression.
Inhibited tumor angiogenesis.
Reduced VEGF immunoreactivity.

Animal Model:

C57BL/6 mice (6-week-old, male)^[2]
Dosage:

5 mg/kg
Administration:

i.p. daily for 6 days
Result:

Decreased hemoglobin concentration and CD31 staining.
Inhibited VEGF-induced new vessel formation in vivo.

Animal Model:

10-month-old APP/PS1 transgenic mice^[4]
Dosage:

1, 10 mg/kg
Administration:

i.p. daily for 30 days
Result:

Enhanced the exploration of the novel object by the mice.
Ameliorated learning and memory deficits in APP/PS1mice.
Reduced the level of APP/β-amyloid.
Increased the levels of synapse-associated proteins, including PSD95 and Map2.
Reduced neuronal apoptosis in the cortex and hippocampus.
Increased the SOD content and decreased MDA levels in the hippocampus.
Increased Bcl2 levels, decreased Bax, p-JNK expression, and decreased caspase-3 activation.

Animal Model:

Male Institute of Cancer Research (ICR) mice (SPF grade, 20-22 g, 6 weeks old) injected with LPS (15 mg/kg)^[5]
Dosage:

2.5-10 mg/kg
Administration:

i.p., daily for 5 days
Result:

Improved the lung injury scores.
Reduced the MPO activity in LPS-exposed lung tissue.
Reduced the levels of PGE2, IL-1β, IL-6, and TNF-α.

Chemical Information

CAS. Nr. 957-66-4
Appearance Solid
Molecular Weight 244.29
Formel C₁₅H₁₆O₃
Color White to off-white
SMILES

C=C[C@@]1([C@]2([H])[C@](OC(C2=C)=O)([H])C3=C(OC=C3C)C1)C
Structure Classification
- Terpenoids
- Sesquiterpenes
Initial Source
Versand

Room temperature in continental US; may vary elsewhere.
Speicherung

4°C, sealed storage, away from moisture and light

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)

Publications (1)

All

Sort by:

Journal Impact Factor

Eur J Pharmacol

Isolinderalactone targets TNF-α/STAT3 inflammatory pathways to attenuate psoriasis-like dermatitis. [Abstract]

2026 Mar 28:1019:178733. PMID: 41795538

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : 50 mg/mL (204.67 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

4.0935 mL

20.4675 mL

40.9350 mL

5 mM

0.8187 mL

4.0935 mL

8.1870 mL

10 mM

0.4093 mL

2.0467 mL

4.0935 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 5 mg/mL (20.47 mM); Clear solution

This protocol yields a clear solution of ≥ 5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (50.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (301 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Hwang JY, et al. Isolinderalactone regulates the BCL-2/caspase-3/PARP pathway and suppresses tumor growth in a human glioblastoma multiforme xenograft mouse model. Cancer Lett. 2019 Feb 28;443:25-33. [Content Brief]

[2]. Park JH, et al. Isolinderalactone suppresses human glioblastoma growth and angiogenic activity in 3D microfluidic chip and in vivo mouse models. [Content Brief]

[3]. Kwak AW, et al. Isolinderalactone sensitizes oxaliplatin-resistance colorectal cancer cells through JNK/p38 MAPK signaling pathways. Phytomedicine. 2022 Oct;105:154383. [Content Brief]

[4]. Xiong L, et al. Isolinderalactone Ameliorates the Pathology of Alzheimer's Disease by Inhibiting the JNK Signaling Pathway. J Nat Prod. 2023 Dec 22;86(12):2718-2729. [Content Brief]

[5]. Shen X, et al. A natural sesquiterpene lactone isolinderalactone attenuates lipopolysaccharide-induced inflammatory response and acute lung injury through inhibition of NF-κB pathway and activation Nrf2 pathway in macrophages. Int Immunopharmacol. 2023 Nov;124(Pt B):110965. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	4.0935 mL	20.4675 mL	40.9350 mL	102.3374 mL
	5 mM	0.8187 mL	4.0935 mL	8.1870 mL	20.4675 mL
	10 mM	0.4093 mL	2.0467 mL	4.0935 mL	10.2337 mL
	15 mM	0.2729 mL	1.3645 mL	2.7290 mL	6.8225 mL
	20 mM	0.2047 mL	1.0234 mL	2.0467 mL	5.1169 mL
	25 mM	0.1637 mL	0.8187 mL	1.6374 mL	4.0935 mL
	30 mM	0.1364 mL	0.6822 mL	1.3645 mL	3.4112 mL
	40 mM	0.1023 mL	0.5117 mL	1.0234 mL	2.5584 mL
	50 mM	0.0819 mL	0.4093 mL	0.8187 mL	2.0467 mL
	60 mM	0.0682 mL	0.3411 mL	0.6822 mL	1.7056 mL
	80 mM	0.0512 mL	0.2558 mL	0.5117 mL	1.2792 mL
	100 mM	0.0409 mL	0.2047 mL	0.4093 mL	1.0234 mL

Isolinderalactone

1 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

Isolinderalactone

Apoptosis Compound Library

Immunology/Inflammation Compound Library

JAK/STAT Compound Library

Kinase Inhibitor Library

NF-κB Signaling Compound Library

Protein Tyrosine Kinase Compound Library

Stem Cell Signaling Compound Library

Natural Product Library

Anti-Cancer Compound Library

Anti-Aging Compound Library

Antioxidant Compound Library

Differentiation Inducing Compound Library

Reprogramming Compound Library

Oxygen Sensing Compound Library

Endoplasmic Reticulum Stress Compound Library

Terpenoids Library

Pyroptosis Compound Library

Traditional Chinese Medicine Active Compound Library

Anti-Alzheimer's Disease Compound Library

Neuroprotective Compound Library

Anti-Breast Cancer Compound Library

Anti-Lung Cancer Compound Library

Anti-Pancreatic Cancer Compound Library

Anti-Blood Cancer Compound Library

Anti-Cancer Metabolism Compound Library

Neurodegenerative Disease-related Compound Library

Anti-Obesity Compound Library

Angiogenesis-Related Compound Library

Mitochondria-Targeted Compound Library

Transcription Factor-Targeted Library

Anti-Liver Cancer Compound Library

Anti-Colorectal Cancer Compound Library

Anti-Cancer Natural Product Library

Antidepressant Compound Library

Anti-inflammatory Traditional Chinese Medicine Active Compound Library

Plant-Sourced Natural Product Library

Anti-Prostate Cancer Compound Library

Anti-Pulmonary Fibrosis Compound Library

Cancer Stem Cells Compound Library

Heterocyclic Compound Library

Pain-Related Compound Library

Membrane Protein-targeted Compound Library

Membrane Receptor-targeted Compound Library

Cytokine Inhibitors Library

Cell Death Library

Anti-Hematopathy Compound Library

Anti-Ovarian Cancer Compound Library

Macrophage Related Compound Library

Multi-Target Compound Library

Radioprotector Library

Mitophagy Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Natural Product Library Plus

Natural Product and Natural Product-Like Compound Library

Bioactive Compound Library

Anti-Gastric Cancer Compound Library

Anti-Fibrosis Compound Library

Anti-Brain Cancer Compound Library

Protein Kinase Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

RO5 Drug-like Natural Product Library

Cell Proliferation Compound Library

High-Throughput Bioactive Compound Library

High-Throughput Natural Product Library

Ancient Chinese Classical Formulas Traditional Chinese Medicine Active Compound Library

Diarrhea-Related Traditional Chinese Medicine Active Compound Library

Posttranslational Modification Library

Natural Product Diversity Scaffold Library

RNA Binding Bioactive Compound Library

Lactylation Compound Library

Mass Spectrometry Natural Product Library

Publications Citing Use of MedChemExpress (MCE) Isolinderalactone

Alle STAT Isoform-spezifische Produkte anzeigen

Alle VEGFR Isoform-spezifische Produkte anzeigen

Alle Bcl-2 Family Isoform-spezifische Produkte anzeigen

Alle IAP Isoform-spezifische Produkte anzeigen

Alle NF-κB Isoform-spezifische Produkte anzeigen

Alle Caspase Isoform-spezifische Produkte anzeigen